Research Studies
How do I learn more about current open studies?
Below you will find a list of current studies. Clicking on the link will take you to the study summary, which will provide you with all the important details for each study.
How do I participate in a study?
Each study summary provides a list of hospitals or clinics where the study is being run. Using the contact information provided, you may contact any of these facilities in order to request participation in a study.
Showing All Ongoing CEGIR Studies
Recruiting
7801: A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EoG), Colitis (EoC) and Enteritis (EoN)
CEGIR is conducting this study because they want to learn more about Eosinophilic Gastrointestinal Diseases (EGIDs). As part of that goal, one area of study will compare how well a patient feels – their symptoms – with what the tissue samples look like under a microscope. The study aims to answer a series of questions, including the following: - What if the tissue looks good, but you are still experiencing symptoms? - What if the symptoms have subsided, but the eosinophil counts haven’t changed?
7810: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (ANTI-IL4RA) in Subjects with Eosinophilic Gastritis
This study is being conducted to determine the safety and effectiveness of a study drug called dupilumab in adolescents and adults with eosinophilic gastritis (EG) with or without esophageal and/or duodenal eosinophilia.
7811: An Open-Label Study Of Zemaira (Alpha 1-Trypsin Inhibitor) In Subjects With Eosinophilic Esophagitis
This is a phase 2, open-label trial testing the efficacy and safety of Zemaira in EoE. Qualifying participants will receive weekly intravenous infusions of 120 mg/kg body weight (BW) dose/week for 12 weeks for a total of 12 infusions. All participants will be followed for an additional 12 weeks after the last dose of study drug.